Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032
Overview
The Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is expected to reach a 23.83 USD Million by 2032 and is projected to grow at a CAGR of 11.56% from 2025 to 2032.
Revenue, 2024 (USD Million)
12.27
Forecast, 2032 (USD Million)
23.83
CAGR, 2024 - 2032
11.56%
Report Coverage
Argentina
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market 2018-2032 USD Million
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 12.27 USD Million
- Projected Market Size (2032): 23.83 USD Million
- CAGR (2025-2032): 11.56%
Key Findings of Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market
- The Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at 12.27 USD Million in 2024.
- The Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is likely to grow at a CAGR of 11.56% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Parenteral in Route of Administration Segment accounted for the largest share of the market with a revenue of 9.25 USD Million
- The fastest growing segment Inhalation of Harmful Substances in Cause Segment grew Fastest with a CAGR of 12.35% during the forecast period from 2024 to 2032.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Scope
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segmentation & Scope
Cause
- Others
- Severe Pneumonia
- Inhalation of Harmful Substances
- Sepsis
Route of Administration
- Others
- Oral
- Parenteral
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Distribution Channel
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
- Direct Tender
Type
- Others
- Tocilizumab
- Extracorporeal Membrane Oxygenation (ECMO)
- Antiviral Medication
- Corticosteroids
- Mechanical Ventilation
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 12.27 USD Million |
| Market Value in 2032 | 23.83 USD Million |
| CAGR (2025-2032) | 11.56% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Cause ,Route of Administration ,End User,Distribution Channel,Type |
Regional Insights:
-
Leading Market (2024-2032): Argentina, leading in terms of revenue 12.27 USD Million in 2024
- Key Country: Argentina, leading in terms of revenue with value of 12.27 USD Million in 2024.
Segments and Scope
-
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Cause
- Sepsis is the largest segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 7.24 USD Million in the year 2024.
- Inhalation of Harmful Substances is the Fastest growing segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 11.75 % in forecast period 2025-2032.
-
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Route of Administration
- Parenteral is the largest segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 9.25 USD Million in the year 2024.
- Parenteral is the Fastest growing segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 11.89 % in forecast period 2025-2032.
-
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By End User
- Hospitals is the largest segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 8.77 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 11.77 % in forecast period 2025-2032.
-
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 7.49 USD Million in the year 2024.
- Direct Tender is the Fastest growing segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 12.11 % in forecast period 2025-2032.
-
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032, By Type
- Mechanical Ventilation is the largest segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a revenue of 6.14 USD Million in the year 2024.
- Mechanical Ventilation is the Fastest growing segment in Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market to 2032 with a Growth rate of 12.19 % in forecast period 2025-2032.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Company Share Analysis
| Company Name |
|
||
| Medtronic | |||
| LivaNova | |||
| Terumo Corporation | |||
| Getinge AB | |||
| Gilead Sciences, Inc. | |||
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Geographical Sales Distribution, 2018-2032 USD Million
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is segmented based on Segmentation Cause ,Route of Administration ,End User,Distribution Channel,Type.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 12.27(Revenue in USD Million) in 2021.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to grow at a CAGR of 11.56% during the forecast period of 2024 to 2032.
The Parenteral segment is expected to dominate the Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market, holding a largest market share of 9.25 USD Million in 2024
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Scope
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Segmentation & Scope
Cause
- Others
- Severe Pneumonia
- Inhalation of Harmful Substances
- Sepsis
Route of Administration
- Others
- Oral
- Parenteral
End User
- Others
- Home Healthcare
- Specialty Clinics
- Hospitals
Distribution Channel
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
- Direct Tender
Type
- Others
- Tocilizumab
- Extracorporeal Membrane Oxygenation (ECMO)
- Antiviral Medication
- Corticosteroids
- Mechanical Ventilation
Frequently Asked Questions
The Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is segmented based on Segmentation Cause ,Route of Administration ,End User,Distribution Channel,Type.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 12.27(Revenue in USD Million) in 2021.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to grow at a CAGR of 11.56% during the forecast period of 2024 to 2032.
The estimated market value of the Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market for final year is USD 23.83 (USD Million).
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market Company Profiling
Frequently Asked Questions
The Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is segmented based on Segmentation Cause ,Route of Administration ,End User,Distribution Channel,Type.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 12.27(Revenue in USD Million) in 2021.
Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to grow at a CAGR of 11.56% during the forecast period of 2024 to 2032.
The estimated market value of the Argentina Acute Respiratory Distress Syndrome (ARDS) Treatment Market for final year is USD 23.83 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.